Singapore markets closed

Genetron Holdings Limited (GTH)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.0250+0.0050 (+0.12%)
At close: 04:00PM EDT
4.0201 -0.00 (-0.12%)
After hours: 06:19PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.0200
Open4.0200
Bid4.0100 x 2000
Ask4.0300 x 2000
Day's range4.0200 - 4.0500
52-week range2.0790 - 4.0500
Volume412,380
Avg. volume51,636
Market cap127.288M
Beta (5Y monthly)0.50
PE ratio (TTM)N/A
EPS (TTM)-3.6200
Earnings date18 Jan 2024 - 19 Jan 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Genetron Health Announces Completion of Going Private Transaction

    BEIJING, March 28, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today the completion of its merger (the “Merger”) with Genetron New Co Limited (“Merger Sub”), pursuant to the previously announced agreement and plan of merger, dated as of October 11, 2

  • GlobeNewswire

    Genetron Health Announces Shareholders’ Approval of Merger Agreement

    BEIJING, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that at an extraordinary general meeting of shareholders (the “EGM”) held today, the Company’s shareholders voted in favor of, among other things, the proposal to authorize and appro

  • GlobeNewswire

    Genetron Health to Hold Extraordinary General Meeting of Shareholders

    BEIJING, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has called an extraordinary general meeting of shareholders (the “EGM”), to be held at on February 21, 2024 at 9:00 a.m. (Beijing time) at 1/F, Building 11, Zone 1, No. 8 Lif